EUCTR2005-002800-40-CZ进行中（未招募）不适用
Prospective, Open-label, Comparative, Multicenter Study of Voriconazole Compared to Itraconazole for the Primary Prophylaxis of Invasive Fungal Infections (IFI) in Subjects with Allogeneic Hematopoietic Stem Cell Transplants (HSCT) - N/A
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Pfizer Ltd.
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:
- •·Males or females = 12 years of age.
- •·Subjects who will be receiving allogeneic HSCT for acute leukemia (AML, ALL or myelodysplastic syndrome) failure of therapy for lymphoma or transformation of chronic myeloid leukemia
- •·Signed and dated informed consent will be obtained from each subject in accordance with the local regulatory and legal requirements
- •·Females of childbearing potential must have a negative serum b-HCG pregnancy test and use an approved method of contraception throughout the study
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects presenting with any of the following must not be included in the trial:
- •·Probable or proven IFI at study entry or at any time in 6 months prior to study entry, defined according to the consensus criteria” (Ascioglu et al 2002 ).
- •·Any previous history of zygomycosis (e.g. Mucor, Absidia, Rhizopus).
- •·Use of any systemically active antifungal agent within the 7 days prior to study entry.
- •·Allergy to study drugs or any excipients.
- •·Abnormal laboratory test results, defined as impaired hepatic function, as shown by transaminases or alkaline phosphatase, > 5 x Upper Limit of Normal [ULN], bilirubin >2.5mg/dL.
- •·Severe disease other than underlying condition, likely to jeopardize the planned termination of the study (e.g. acute myocardial infarction, unstable angina pectoris, potentially pro-arrhythmic conditions such as cardiac impairment due to previous cardiotoxic chemotherapy, previous torsade de pointes, prolongation of the QT interval > 450 msec for men or > 470 msec for women).
- •·Concomitant use of sirolimus, ergot alkaloids, terfenadine, astemizole, cisapride, pimozide, quinidine, carbamazepine, rifampicin, phenobarbital, ritonavir, efavirenz or St. John’s Wort which might interfere with the evaluation of study drugs during the study.
- •· Alcohol and/or any other drug abuse.
- •·Previous participation in this trial.
- •·Unable and/or unlikely to comprehend and/or follow the protocol.
- •·Participation in any other studies involving investigational products, concomitantly or within 30 days prior to entry in the study.
- •·Anticipated survival less than one month.
研究者
相似试验
进行中（未招募）
1 期
Prospective, Open-label, Comparative, Multicenter Study of Voriconazole Compared to Itraconazole for the Primary Prophylaxis of Invasive Fungal Infections (IFI) in Subjects with Allogeneic Hematopoietic Stem Cell Transplants (HSCT) - N/AProphylaxis against invasive fungal infection following allogeneic hematopoietic stem cell transplantation.MedDRA version: 8 Classification code 10017533EUCTR2005-002800-40-GBPfizer Ltd489
进行中（未招募）
不适用
Prospective, Open-label, Comparative, Multicenter Study of Voriconazole Compared to Itraconazole for the Primary Prophylaxis of Invasive Fungal Infections (IFI) in Subjects with Allogeneic Hematopoietic Stem Cell Transplants (HSCT) - N/AProphylaxis against invasive fungal infection following allogeneic hematopoietic stem cell transplantation.MedDRA version: 8Classification code 10017533EUCTR2005-002800-40-PT500
进行中（未招募）
1 期
Prospective, Open-label, Comparative, Multicenter Study of Voriconazole Compared to Itraconazole for the Primary Prophylaxis of Invasive Fungal Infections (IFI) in Subjects with Allogeneic Hematopoietic Stem Cell Transplants (HSCT)EUCTR2005-002800-40-ESaboratorios Pfizer S.A489
进行中（未招募）
不适用
Prospective, Open-label, Comparative, Multicenter Study of Voriconazole Compared to Itraconazole for the Primary Prophylaxis of Invasive Fungal Infections (IFI) in Subjects with Allogeneic Hematopoietic Stem Cell Transplants (HSCT) - N/AProphylaxis against invasive fungal infection following allogeneic hematopoietic stem cell transplantation.MedDRA version: 8Classification code 10017533EUCTR2005-002800-40-GR500
已完成
不适用
PORTRAIT studyHypertgemiaD050171JPRN-jRCTs041200011Sumida Yoshio80